|Bid||95.72 x 3000|
|Ask||99.12 x 800|
|Day's range||95.33 - 97.40|
|52-week range||76.41 - 100.15|
|Beta (3Y Monthly)||0.62|
|PE ratio (TTM)||41.95|
|Earnings date||20 Nov 2018|
|Forward dividend & yield||2.00 (2.11%)|
|1y target est||103.90|
In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depositary share (or $29.25 per ordinary share), which amounts to a total of $1.64 billion (or $1.34 billion). Both companies’ boards of directors unanimously approved the transaction.
Medtronic’s (MDT) Cardiac & Vascular Group consists of cardiac rhythm and heart failure, coronary and structural heart, aortic, and peripheral and venous products. Medtronic’s Cardiac and Vascular Group generated revenues of $2.8 billion in the first quarter of fiscal 2019 compared to $2.6 billion in the first quarter of fiscal 2018, a ~6% year-over-year (or YoY) increase.
Jim Cramer zips through his take on callers' favorite stocks, including a technology hardware giant in the throes of marketwide weakness.
Medtronic’s (MDT) Restorative Therapies Group consists of spine, brain, specialty, and pain therapies. The segment generated net revenues of $1.9 billion in the first quarter of fiscal 2019 compared to $1.8 billion in the first quarter of fiscal 2018, reflecting an ~8% YoY increase.
In the first quarter of fiscal 2019, Medtronic generated net revenues of $7.4 billion, a ~0.1% year-over-year (or YoY) decline. Wall Street analysts estimate that Medtronic will generate revenues of $7.3 billion in the second quarter of fiscal 2019.
How Is Medtronic Positioned in October? On October 12, Medtronic stock closed at $94.69, which is a ~1.7% rise from its prior-day close of $93.11 on October 11 and a ~24% rise from its 52-week low of $76.41. Medtronic hit its 52-week high of $100.15 on September 26, 2018.
Edwards Lifesciences (EW) is a leading transcatheter heart valve manufacturer in the United States. The company is set to release its third-quarter earnings results after the market closes on October 23. In this article, we’ll look at analysts’ recommendations and target prices for EW ahead of its third-quarter earnings release. According to an October 12 Reuters survey, which included 21 analysts covering EW stock, 62% of analysts (or 13) have recommended “buys” or “strong buys” on Edwards Lifesciences.
Johnson & Johnson’s (JNJ) Medical Device business has posted steadily improving performance in recent quarters. Since then, Johnson & Johnson has efficiently implemented a restructuring plan for its Medical Device business, which resulted in significant growth in the segment’s performance. In the second quarter, Johnson & Johnson’s Medical Device business reported sales of ~$7.0 billion, which contributed 33.5% to the company’s total sales of $20.8 billion.
Johnson & Johnson (JNJ) is scheduled to report its third-quarter earnings on October 16. The company’s second-quarter growth in its Consumer business was below expectations. However, it expects to accelerate the segment’s growth in the second half of the year, driven mainly by the introduction of new products. The company’s other two business segments are Pharmaceuticals and Medical Devices. Johnson & Johnson’s Consumer business consists of a range of products across its baby care, oral care, women’s health, beauty, wound care, and over-the-counter franchises.
On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close. On the day, Morgan Stanley raised its target price on ABT stock from $70 to $80. However, the stock price dropped as the broader market sell-off pulled down ABT stock prices along with a large number of other healthcare stocks. The SPDR S&P 500 ETF (SPY) was down ~3.2% on October 10.
Abbott Laboratories (ABT) is slated to announce its Q3 earnings results on October 17. Let’s look at Wall Street analysts’ recommendations for ABT stock ahead of its earnings release.
Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% from $227.5 million in the third quarter of 2017 to $265.76 million in the third quarter of 2018. In the third quarter, Intuitive Surgical is expected to incur selling, general, and administrative expenses of $207.11 million compared to $204.8 million in the third quarter of 2017, reflecting a potential increase of 1.13%. Intuitive Surgical is expected to report net income of $258.28 million in the third quarter compared to net income of $297.5 million in the third quarter of 2017, indicating a contraction of 13.18% in the company’s net margins.
Eleven of the 18 analysts covering Intuitive Surgical (ISRG) in October have given the stock “buy” or higher ratings. Six analysts have given it “hold” ratings, and one has given it a “sell” rating.
Americans depend on wearable medical devices for fitness tracking, blood pressure maintenance, self-glucose monitoring and more. Here, we discuss major companies that are raking in huge profits.
On October 4, Boston Scientific (BSX) was trading at a forward PE ratio of 24.7x compared to the industry average of 22.9x. Let’s look at another key valuation multiple, the EV-to-EBITDA ratio, which is a capital structure–neutral valuation metric. Boston Scientific’s forward EV-to-EBITDA multiple is 19.4x, which is higher than the industry average of 17.3x.
Boston Scientific (BSX) stock traded at its 52-week high on October 2. It has seen tremendous growth momentum over the past year on the back of strong product launches, approvals, and acquisitions.
Boston Scientific Has Massive Bull Run: Is There More Upside? On October 3, Boston Scientific (BSX) stock closed at $38.61, a decline of ~1.1% compared to $39.04 on October 2. It hit a 52-week high of $39.44 during the day on October 2 when Morgan Stanely raised its target price.
On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close. The stock registered a 52-week high of $74.15 on October 1. Throughout the week, it’s fallen ~1.6%.
NEW YORK, Oct. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products. During the second quarter of 2018, the Pharmaceutical segment reported a 1% increase in operating revenues to ~4.23 billion pounds.